Patents by Inventor Benedetto FARSACI

Benedetto FARSACI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT
    Publication number: 20220298243
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Application
    Filed: April 7, 2022
    Publication date: September 22, 2022
    Applicants: Bristol-Myers Squibb Company, Seattle Genetics, Inc.
    Inventors: Benedetto FARSACI, Neil JOSEPHSON, Anthony CAO, Ryan HEISER
  • CYTOKINE PROFILING ANALYSIS
    Publication number: 20220155320
    Abstract: This invention relates to methods for predicting a prognosis of a patient with cancer in need of an anti-cancer treatment comprising measuring a cytokine score from a sample obtained from the patient. In some embodiments, the subject is administered an anti-cancer treatment, e.g., an anti-PD-1 antibody, following the cytokine score measurement. In some embodiments, the cancer is lung cancer.
    Type: Application
    Filed: November 19, 2021
    Publication date: May 19, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventor: Benedetto FARSACI
  • Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment
    Patent number: 11299543
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: April 12, 2022
    Assignees: Bristol-Myers Squibb Company, Seattle Genetics. Tnc.
    Inventors: Benedetto Farsaci, Neil Josephson, Anthony Cao, Ryan Heiser
  • TREATMENT OF HODGKIN LYMPHOMA USING AN ANTI-PD-1 ANTIBODY
    Publication number: 20220025049
    Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody to a subject, wherein the subject has received at least one prior treatment for Hodgkin lymphoma.
    Type: Application
    Filed: August 9, 2021
    Publication date: January 27, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventor: Benedetto FARSACI
  • Cytokine profiling analysis
    Patent number: 11209441
    Abstract: This invention relates to methods for predicting a prognosis of a patient with cancer in need of an anti-cancer treatment comprising measuring a cytokine score from a sample obtained from the patient. In some embodiments, the subject is administered an anti-cancer treatment, e.g., an anti-PD-1 antibody, following the cytokine score measurement. In some embodiments, the cancer is lung cancer.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: December 28, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventor: Benedetto Farsaci
  • Treatment of Hodgkin lymphoma using an anti-PD-1 antibody
    Patent number: 11083790
    Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 10, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventor: Benedetto Farsaci
  • TREATMENT OF HODGKIN LYMPHOMA USING AN ANTI-PD-1 ANTIBODY
    Publication number: 20190290757
    Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.
    Type: Application
    Filed: June 1, 2017
    Publication date: September 26, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventor: Benedetto FARSACI
  • USE OF AN ANTI-PD-1 ANTIBODY IN COMBINATION WITH AN ANTI-CD30 ANTIBODY IN CANCER TREATMENT
    Publication number: 20190218293
    Abstract: The application provides to methods for treating Hodgkin lymphoma or non Hodgkin lymphoma in a subject comprising—nivolumab, or pembrolizumab, two PD-1-blocking antibodies that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma in combination with—an anti CD30 antibody, such as brentuximab vedotin.
    Type: Application
    Filed: June 1, 2017
    Publication date: July 18, 2019
    Applicants: Bristol-Myers Squibb Company, Seattle Genetics, Inc.
    Inventors: Benedetto FARSACI, Neil JOSEPHSON, Anthony CAO, Ryan HEISER
  • CYTOKINE PROFILING ANALYSIS
    Publication number: 20190154701
    Abstract: This invention relates to methods for predicting a prognosis of a patient with cancer in need of an anti-cancer treatment comprising measuring a cytokine score from a sample obtained from the patient. In some embodiments, the subject is administered an anti-cancer treatment, e.g., an anti-PD-1 antibody, following the cytokine score measurement. In some embodiments, the cancer is lung cancer.
    Type: Application
    Filed: April 5, 2017
    Publication date: May 23, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventor: Benedetto FARSACI